Arcutis Biotherapeutics Inc

NASDAQ: ARQT
$9.83
+$1.51 (+18.1%)
Closing Price on August 23, 2024

ARQT Chart and Intraday Price

ARQT Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,139.49M USD
Shares Outstanding 96,813,000
Arcutis Biotherapeutics Inc is a biopharmaceutical firm dedicated to crafting and bringing to market treatments for skin conditions. With a leading product, ARQ-151, aimed at addressing plaque psoriasis and atopic dermatitis, the company is at the forefront of dermatological innovation. Their pipeline also includes solutions for scalp psoriasis, seborrheic dermatitis, hand eczema, vitiligo, and alopecia areata, showcasing their commitment to tackling a wide range of dermatological challenges. Founded in 2016 and based in Westlake Village, California, Arcutis is pushing the boundaries of skin health.

ARQT Articles

Wednesday’s top analyst upgrades and downgrades included Allegro, Jinkosolar, Masco, Micron Technology, Plug Power, Smith & Wesson and Virgin Galactic.
Thursday's top analyst upgrades and downgrades included Airbnb, CrowdStrike, DoorDash, Ford, Intuit, Lumber Liquidators, Occidental Petroleum, T-Mobile, Twilio, Uber and UBS.
Thursday's top analyst upgrades and downgrades included Arcutis Biotherapeutics, DraftKings, First Solar, InflaRx, Livent, Medtronic, NextEra Energy Partners, Roku, Snowflake and Tesla.
24/7 Wall St. tracked six new secondary offerings that were announced after the close on Tuesday, September 29, 2020.